Medical Treatment in China: Advanced Care,
Specialists & Clinical Trials
For an international patient, choosing to travel to another country for medical care is a major decision.
The question is not simply whether China has modern hospitals or qualified doctors. Most developed healthcare systems can provide high-quality routine medical care.
A more useful question is: Does China offer a level of specialist experience, treatment technology, case volume, or access to emerging therapies that could make traveling for care worthwhile in my particular case?
For some patients, the answer may be yes.
China has developed several extremely high-volume specialist medical centers, particularly in oncology, cardiovascular medicine, neurosurgery, ophthalmology, rare diseases, and advanced interventional treatment. In some fields, leading hospitals treat tens of thousands of complex cases each year, giving specialist teams substantial experience with uncommon or technically difficult conditions.
China has also become an increasingly active environment for clinical research, including cell therapies, targeted drugs, immunotherapies, advanced radiation techniques, and new medical devices.
However, these advantages are not relevant to every patient. The value of seeking treatment in China depends on the disease, stage, previous treatment, available alternatives at home, and the expertise of the specific hospital and medical team.
The following areas illustrate where China may offer particularly significant medical resources.
1. Cancer Treatment: High-Volume Centers and Advanced Treatment Options
Cancer care is one of the strongest areas to consider when evaluating medical treatment in China.
Large cancer centers in Beijing, Shanghai, Guangzhou and other major cities manage very high numbers of cancer patients and often organize treatment around individual disease-specific teams rather than general oncology departments.
Conditions commonly treated at major Chinese cancer centers include:
Lung cancer
Gastric and gastroesophageal junction cancer
Liver cancer
Nasopharyngeal cancer
Head and neck cancers
Colorectal cancer
Breast cancer
Prostate cancer
Pancreatic cancer
Esophageal cancer
Lymphoma
Sarcoma
Brain tumors
Gynecological cancers
Rare and recurrent solid tumors
High Patient Volumes Can Create Concentrated Clinical Experience
Sun Yat-sen University Cancer Center in Guangzhou, for example, reports more than 2 million outpatient and emergency visits annually, approximately 200,000 inpatient cases, and close to 50,000 surgical procedures per year. Its clinical services include surgery, medical oncology, radiation oncology, interventional oncology and multidisciplinary cancer treatment.
Its thoracic surgery department alone manages lung, esophageal, mediastinal and other thoracic tumors and performs approximately 4,900 operations annually.
Its interventional oncology department reports more than 16,000 minimally invasive interventional procedures per year, including radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, radioactive seed implantation, hepatic arterial infusion chemotherapy and other tumor-directed therapies.
For international patients with complicated, recurrent or previously treated cancers, this type of concentrated disease-specific experience can be particularly relevant.
High case volume alone does not guarantee a better result. However, it can mean that specialist teams are regularly exposed to complex anatomy, unusual disease presentations and treatment complications that lower-volume centers may encounter less frequently.
2. Proton and Carbon-Ion Therapy
One of the more distinctive cancer-treatment resources available in China is particle radiation therapy, including both proton therapy and carbon-ion therapy.
These technologies are designed to deliver radiation more precisely to a tumor while reducing radiation exposure to surrounding tissue.
They may be considered in selected patients with tumors such as:
Nasopharyngeal cancer
Skull-base tumors
Recurrent head and neck cancers
Certain brain tumors
Early-stage or medically inoperable lung cancers
Prostate cancer
Pancreatic cancer
Liver tumors
Selected sarcomas
Some recurrent tumors previously treated with radiation
Not every tumor benefits from particle therapy, and eligibility requires specialist radiation-oncology assessment.
Shanghai's Large Particle-Therapy Experience
Shanghai Proton and Heavy Ion Center, affiliated with Fudan University, combines proton and carbon-ion radiation therapy.
By May 2026, the center had treated 9,317 patients with particle therapy, with annual treatment volumes exceeding 1,000 patients for several consecutive years. Its treatment scope has expanded to more than 50 cancer types. Nasopharyngeal cancer, skull-base tumors, lung cancer and breast cancer have each accumulated more than 1,000 treated cases.
The center previously reported that approximately three quarters of its patients receive either carbon-ion therapy alone or carbon-ion therapy combined with proton treatment.
This is important from a cross-border perspective because carbon-ion therapy remains considerably less available globally than conventional photon radiotherapy.
The center has developed dozens of disease-specific particle-radiotherapy protocols and has accumulated substantial experience particularly in nasopharyngeal, skull-base, lung, prostate, pancreatic and other cancers.
For a patient considering particle therapy, the relevant question is therefore not simply:
“Is proton or carbon-ion therapy available in China?”
It is:
“Does my tumor have an indication for particle therapy, and does the treating center have substantial experience with my specific cancer type, location and previous treatment history?”
3. Emerging Cancer Therapies and Clinical Trials
Another reason some patients investigate treatment in China is access to clinical research.
China now has a large regulatory clinical-trial infrastructure. Drug trials conducted for registration in China are required to be registered through the National Medical Products Administration’s Drug Clinical Trial Registration and Information Disclosure Platform.
For patients with advanced cancer who have exhausted standard therapies, relevant research areas may include:
CAR-T cell therapy
TCR-T cell therapy
Tumor-infiltrating lymphocyte therapies
Other genetically modified T-cell therapies
Antibody-drug conjugates
Bispecific antibodies
New immune-checkpoint combinations
Molecularly targeted therapies
Cancer vaccines
Novel therapies for biomarker-defined cancers
CAR-T Beyond Traditional Blood Cancers
CAR-T therapy is already an established treatment approach for selected hematological malignancies.
China has approved multiple cellular therapies. For example, the NMPA conditionally approved ciltacabtagene autoleucel, a BCMA-directed CAR-T therapy, for selected adults with heavily pretreated relapsed or refractory multiple myeloma in 2025.
Chinese investigators are also actively studying whether engineered cell therapies can be extended into solid tumors.
A notable example comes from gastric cancer.
A China-led randomized Phase II study investigated CLDN18.2-targeted CAR-T therapy, satri-cel, in previously treated advanced gastric or gastroesophageal junction cancer. The study was published in The Lancet in 2025 and represented the first randomized controlled trial of a CAR-T therapy in a solid tumor.
This does not mean CAR-T has become standard therapy for most solid tumors. It demonstrates something different: some Chinese oncology centers are participating at the front edge of developing entirely new treatment strategies.
TCR-T, TIL and Other Investigational Cellular Therapies
Clinical-trial recruitment at Sun Yat-sen University Cancer Center has included studies involving:
NY-ESO-1-specific TCR-engineered T cells for advanced solid tumors
Gene-modified TIL-like cellular therapy for recurrent or metastatic EBV-positive nasopharyngeal cancer
Investigational EBV mRNA vaccines for EBV-positive relapsed or refractory lymphoma
Novel therapies for AFP-positive advanced liver cancer
New antibody and immunotherapy combinations for head and neck cancer
New treatment combinations for advanced NSCLC with brain metastases
These are clinical trials rather than established treatments. Participation depends on eligibility criteria such as tumor type, molecular biomarkers, previous therapies, organ function and performance status.
For some heavily pretreated patients, however, access to an appropriate clinical trial may be one of the legitimate reasons to explore treatment outside their home country.
4. Cardiovascular Medicine: Extremely High Procedural Volumes
Cardiovascular medicine is another area in which China’s largest specialist centers operate at unusually high scale.
Fuwai Hospital in Beijing, home to the National Center for Cardiovascular Diseases, reports approximately:
Nearly 20,000 cardiovascular surgical procedures per year
More than 50,000 cardiovascular interventional procedures per year
1,403 hospital beds
27 operating rooms
18 catheterization laboratories
Its extracorporeal circulation center alone supported 15,420 cardiopulmonary bypass procedures in 2024.
Such volumes can be particularly relevant in conditions where outcomes and procedural decision-making depend heavily on specialist experience.
Patients treated include those with:
Complex coronary artery disease
Aortic aneurysm and aortic dissection
Valvular heart disease
Congenital heart disease
Structural heart disease
Arrhythmias
Pulmonary vascular disease
Advanced heart failure
Complex high-risk cardiovascular disease
Advanced Cardiovascular Procedures
Major Chinese cardiovascular centers perform both conventional surgery and increasingly sophisticated catheter-based procedures.
Examples at Fuwai include:
Transcatheter aortic valve replacement (TAVR/TAVI)
Transcatheter pulmonary valve replacement
Transcatheter mitral valve repair and replacement
Transcatheter tricuspid valve procedures
Hybrid cardiac surgery
Minimally invasive coronary bypass surgery
Complex aortic surgery
Percutaneous ventricular assist support
ECMO
Advanced structural-heart interventions
Fuwai reports that its teams introduced 115 new clinical technologies or projects during a recent five-year period, including seven first clinical applications in China and 13 reported as first clinical applications internationally.
This combination of large procedural volume and technology development can make such centers relevant for patients seeking another opinion on a technically complex cardiovascular procedure.
5. Complex Neurosurgery
Certain Chinese hospitals have also developed extremely concentrated expertise in neurosurgery.
Beijing Tiantan Hospital is particularly known for neurological and neurosurgical disease.
Its specialist services manage conditions including:
Gliomas
Skull-base tumors
Brainstem tumors
Deep intracranial tumors
Spinal cord tumors
Cerebrovascular malformations
Complex spinal cord diseases
Congenital neurological disorders
The hospital’s international neurosurgical service describes the use of multimodal imaging before surgery together with intraoperative ultrasound, surgical navigation and electrophysiological monitoring to help maximize tumor removal while attempting to preserve neurological function. Its international neurosurgical ward alone reports approximately 550 operations per year.
A dedicated spinal cord and spinal neurosurgery unit performs more than 1,200 operations annually, treating conditions ranging from spinal cord glioma and vascular malformations to complex congenital abnormalities and spinal cord tumors.
For diseases involving the brainstem, skull base, spinal cord or eloquent areas of the brain, individual surgeon and multidisciplinary team experience may be particularly important because treatment decisions frequently require balancing tumor control against preservation of neurological function.
6. Ophthalmology: Large Subspecialty Case Volumes
Ophthalmology is another specialty where China’s largest dedicated centers operate at substantial scale.
Zhongshan Ophthalmic Center of Sun Yat-sen University reported approximately:
1.566 million outpatient visits annually
113,000 ophthalmic operations annually
Its services include more than ten major ophthalmic subspecialties covering:
Cataract
Corneal disease
Glaucoma
Retinal disease
Vitreoretinal surgery
Ocular trauma
Uveitis
Ocular tumors
Pediatric ophthalmology
Genetic eye disease
Strabismus
Refractive surgery
For patients with uncommon ocular diseases or complex cases involving multiple structures of the eye, large subspecialty centers can provide access to teams whose practices are narrowly focused on individual disease categories.
Again, case volume should be considered together with the experience of the actual physician, available technology and expected outcome—not used as a standalone measure of quality.
7. Rare and Difficult-to-Diagnose Diseases
Sometimes the primary reason for seeking international medical care is not access to surgery.
It is access to a diagnosis.
Patients with rare diseases may spend years moving between specialties before a coherent diagnosis is established because symptoms can involve several organs at the same time.
China has developed a national rare-disease referral system led by Peking Union Medical College Hospital.
The National Health Commission established the National Rare Disease Diagnosis and Treatment Collaborative Network in 2019, with Peking Union Medical College Hospital serving as the national coordinating hospital. The network eventually expanded to more than 320 hospitals.
Peking Union Medical College Hospital’s rare-disease multidisciplinary program has involved more than 40 specialties and hundreds of experts, bringing together fields such as:
Genetics
Neurology
Cardiology
Nephrology
Endocrinology
Rheumatology
Hematology
Ophthalmology
Orthopedics
Pediatrics
Imaging
Pathology
This model can be especially relevant when a patient has unexplained multisystem symptoms, an uncertain genetic diagnosis, an extremely uncommon disorder, or conflicting diagnoses from different specialties.
In such cases, the value of care may lie less in a particular treatment and more in access to a multidisciplinary diagnostic process.
8. Why Case Volume Matters — and Why It Is Not Enough
Large hospitals in China frequently operate at a scale that surprises international patients.
But volume should never be interpreted as:
“More patients automatically means better treatment.”
The real advantage is more specific.
When a specialist treats a large number of patients with the same disease, the medical team may encounter:
More uncommon presentations
More complex surgical anatomy
More recurrent disease
More treatment complications
More patients who have failed previous treatment
More opportunities to refine procedures
Larger clinical datasets
Greater capacity to create disease-specific multidisciplinary teams
This becomes particularly relevant for rare diseases and technically demanding procedures.
For example, a physician who treats hundreds of cases of one specific tumor may have a very different clinical practice from a physician whose department treats that tumor only occasionally.
For an international patient, therefore, the most useful question is not:
“How many patients does the hospital treat?”
It is:
“How many patients with my exact disease and treatment situation does this team treat?”
9. When Could Treatment in China Be Worth Considering?
China may be particularly worth investigating when one or more of the following apply:
You have a complex condition requiring a highly specialized center
Examples include complex congenital heart disease, aortic disease, skull-base tumors, spinal cord tumors, rare eye diseases or difficult recurrent cancers.
You want another expert interpretation of your diagnosis or treatment plan
A second opinion may reveal that another surgical approach, radiation technique, interventional procedure or systemic treatment strategy is possible.
Your disease requires a treatment technology that is difficult to access locally
Examples may include carbon-ion therapy or certain highly specialized cardiovascular or interventional procedures.
Standard cancer treatments have been exhausted
Patients with advanced cancer may investigate biomarker-driven studies, cellular therapies or other clinical trials when conventional treatment options have become limited.
Your diagnosis remains unclear
Patients with rare or multisystem disease may benefit from evaluation by multidisciplinary teams rather than repeatedly consulting isolated specialties.
You have been told that surgery or treatment is technically difficult
Another high-volume specialist center may interpret operability or procedural feasibility differently.
This does not mean another hospital will necessarily recommend treatment. A responsible second opinion can also confirm that further intervention is unlikely to provide meaningful benefit.
10. When Traveling to China May Not Offer a Meaningful Advantage
Cross-border medical care should not be pursued simply because a hospital has advanced technology.
For many routine conditions, appropriate treatment is already available close to home.
Travel may provide limited additional value for:
Routine primary care
Stable chronic diseases already well controlled locally
Standard procedures readily available at home
Conditions requiring frequent long-term follow-up that cannot realistically be coordinated internationally
Medical emergencies where delaying treatment for international travel would create additional risk
The goal should therefore never be to travel simply because treatment is available in China.
The goal is to determine whether China offers something medically relevant to your individual case that is unavailable, inaccessible or meaningfully different from your current options.
How Should an International Patient Evaluate a Chinese Hospital?
Before making travel arrangements, patients should request a case-based assessment.
Useful questions include:
Does the hospital regularly treat my exact condition?
Ask about disease-specific experience rather than overall hospital size.
Which department and physician would review my case?
Hospital reputation matters, but treatment is delivered by a specific medical team.
How many similar cases does the team treat?
This is especially important for rare diseases and complex procedures.
Is the proposed treatment standard therapy or experimental therapy?
Patients should clearly understand whether a treatment is routinely approved, used under a specific indication, or available only through a clinical trial.
What alternatives are available?
A second opinion should compare reasonable options rather than simply recommend the hospital’s own treatment.
Would I need to remain in China after treatment?
Consider recovery time, complications, repeat visits and follow-up requirements.
Can follow-up continue after I return home?
Continuity of care is particularly important for cancer treatment, cardiovascular procedures and complex surgery.
The Real Question Is Not “Is Chinese Healthcare Good?”
China contains thousands of hospitals with very different levels of specialization.
For an international patient, evaluating “healthcare in China” as a whole therefore has limited value.
A more precise decision looks like this:
My disease
→ the relevant specialty
→ the right hospital
→ the appropriate expert team
→ available treatment options
→ expected benefit and risk
→ whether traveling provides a meaningful advantage.
China’s strongest argument as a cross-border treatment destination is not that every medical service is superior.
It is that selected Chinese medical centers combine very large disease-specific case volumes, highly specialized teams, advanced procedural technologies and increasingly active clinical-research programs.
For certain cancers, cardiovascular diseases, neurological disorders, rare diseases and other complex conditions, those resources may justify obtaining a specialist assessment or second opinion.
Whether they justify actually traveling to China can only be determined after the patient’s diagnosis, previous treatment, imaging, pathology and medical records have been reviewed.
Before Deciding to Travel
If you are considering medical treatment in China, obtaining an initial case review before arranging travel can help determine:
Whether your condition is suitable for evaluation in China
Which specialty or hospital may be relevant
Whether additional medical records or tests are required
Whether a second opinion can be completed remotely first
What treatment options may reasonably be considered
Whether an available clinical trial may be relevant
Whether traveling to China is medically justified at all
The purpose of a case review is not to encourage every patient to travel.
It is to answer the more important question:
Does China offer a medical resource or treatment opportunity that is genuinely relevant to my case?
Medical information on this page is provided for general informational purposes and does not constitute medical advice, diagnosis, or a guarantee of treatment eligibility or outcome. Treatment options, clinical-trial availability and eligibility criteria can change and should be confirmed directly with the treating medical institution.